Impact of cardiovascular risk factors and inflammatory status on urinary 8-OHdG in essential hypertension

American Journal of Hypertension

Volumn 25, Issue 2, 2012, Pages 236-242

  Roselló Lletí, Esther ^a   De Burgos, Fernando García ^b   Morillas, Pedro ^c   Cortés, Raquel ^a   Martínez Dolz, Luis ^a   Almenar, Luis ^a   Grigorian, Lilian ^d   Orosa, Plácido ^e   Portolés, Manuel ^a   Bertomeu, Vicente ^c   Rivera, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Hospital General   (Spain)

^c HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^d HOSPITAL DO MEIXOEIRO   (Spain)

^e Hospital San Francesc de Borja   (Spain)

Author keywords

8 OHdG; blood pressure; hypertension; hypertrophy; oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CREATININE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; URINE LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DEOXYGUANOSINE; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856033319     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.202     Document Type: Article

References (40)

1. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ; Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23:434-439. (Pubitemid 36337219)
2. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339:1-9. (Pubitemid 37542453)
3. Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sáez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41:1096-1101. (Pubitemid 36548609)
4. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49:241-248. (Pubitemid 46142995)
5. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80:45-51. (Pubitemid 27030367)
6. Wu R, Millette E, Wu L, de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2001; 19:741-748. (Pubitemid 32289554)
7. Park JB, Touyz RM, Chen X, Schiffrin EL. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 2002; 15:78-84. (Pubitemid 34102277)
8. Ward NC, Croft KD. Hypertension and oxidative stress. Clin Exp Pharmacol Physiol 2006; 33:872-876. (Pubitemid 44215147)
9. Cottone S, Mulè G, Nardi E, Vadalà A, Guarneri M, Briolotta C, Arsena R, Palermo A, Riccobene R, Cerasola G. Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens 2006; 19: 313-318. (Pubitemid 43261515)
10. Cottone S, Mulè G, Nardi E, Vadalà A, Lorito MC, Guarneri M, Arsena R, Palermo A, Cerasola G. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension. J Hypertens 2007; 25:423-428. (Pubitemid 46071941)
11. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003; 5:731-740. (Pubitemid 37462056)
12. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006; 71:208-215.
13. Simic MG. Urinary biomarkers and the rate of DNA damage in carcinogenesis and anticarcinogenesis. Mutat Res 1992; 267:277-290.
14. Espinosa O, Jiménez-Almazán J, Chaves FJ, Tormos MC, Clapes S, Iradi A, Salvador A, Fandos M, Redón J, Sáez GT. Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG), a reliable oxidative stress marker in hypertension. Free Radic Res 2007; 41:546-554. (Pubitemid 46511119)
15. Abdilla N, Tormo MC, Fabia MJ, Chaves FJ, Saez G, Redon J. Impact of the components of metabolic syndrome on oxidative stress and enzymatic antioxidant activity in essential hypertension. J Hum Hypertens 2007; 21:68-75. (Pubitemid 44921821)
16. Fandos M, Corella D, Guillén M, Portolés O, Carrasco P, Iradi A, Martínez-González MA, Estruch R, Covas MI, Lamuela-Raventós RM, Michavilla MT, Cerdá C, Torregrosa R, Redón J, Chaves FF, Tormos MC, Ocete D, Sáez GT. Impact of cardiovascular risk factors on oxidative stress and DNA damage in a high risk Mediterranean population. Free Radic Res 2009; 43:1179-1186.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470. (Pubitemid 29135798)
19. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
20. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32:865-875. (Pubitemid 28459571)
21. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458. (Pubitemid 16119719)
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
23. Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bächler JP. Relationship between oxidative stress and essential hypertension. Hypertens Res 2007; 30:1159-1167. (Pubitemid 351176413)
24. Sakano N, Wang DH, Takahashi N, Wang B, Sauriasari R, Kanbara S, Sato Y, Takigawa T, Takaki J, Ogino K. Oxidative stress biomarkers and lifestyles in Japanese healthy people. J Clin Biochem Nutr 2009; 44:185-195.
25. Yano T, Shoji F, Baba H, Koga T, Shiraishi T, Orita H, Kohno H. Significance of the urinary 8-OHdG level as an oxidative stress marker in lung cancer patients. Lung Cancer 2009; 63:111-114.
26. Bernhard D, Wang XL. Smoking, oxidative stress and cardiovascular diseases-do anti-oxidative therapies fail? Curr Med Chem 2007; 14:1703-1712. (Pubitemid 47163408)
27. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 2006; 48:278-285. (Pubitemid 44309824)
28. Nakamura K, Barzi F, Lam TH, Huxley R, Feigin VL, Ueshima H, Woo J, Gu D, Ohkubo T, Lawes CM, Suh I, Woodward M; Asia Pacific Cohort Studies Collaboration. Cigarette smoking, systolic blood pressure, and cardiovascular diseases in the Asia-Pacific region. Stroke 2008; 39:1694-1702.
29. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol 2007; 5:276-292.
30. Roselló-Lletí E, Rivera M, Martínez-Dolz L, González Juanatey JR, Cortés R, Jordán A, Morillas P, Lauwers C, Calabuig JR, Antorrena I, de Rivas B, Portolés M, Bertomeu V. Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens 2009; 22:444-450.
31. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153. (Pubitemid 30253042)
32. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772. (Pubitemid 30213096)
33. Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C. Essential hypertension: is there a role for inflammatory mechanisms? Cardiol Rev 2009; 17:216-221.
34. Meldrum DR, Dinarello CA, Cleveland JC Jr, Cain BS, Shames BD, Meng X, Harken AH. Hydrogen peroxide induces tumor necrosis factor α-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery 1998; 124:291-6; discussion 297.
35. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation 1998; 98: 794-799. (Pubitemid 28391845)
36. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Matsushima K, Takeshita A. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101:305-310. (Pubitemid 30054158)
37. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94:1543-1553. (Pubitemid 38856961)
38. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46:735-739. (Pubitemid 44378243)
39. Sáez GT, Tormos C, Giner V, Chaves J, Lozano JV, Iradi A, Redón J. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am J Hypertens 2004; 17:809-816. (Pubitemid 39201097)
40. Mayosi BM, Keavney B, Kardos A, Davies CH, Ratcliffe PJ, Farrall M, Watkins H. Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. Eur Heart J 2002; 23:1963-1971. (Pubitemid 35448555)